The formation of the European CLL Association – ECLLA marks a critical step forward in addressing persistent inequalities in chronic lymphocytic leukemia care across Europe. By uniting clinicians, researchers, patient advocates and partners around a common mission ensuring that every person living with CLL in Europe receives equitable, informed and optimal care.
While Western European countries often provide broader access to modern CLL therapies, significant regional disparities in access, policy frameworks, diagnostic support, and clinician/patient education persist across Europe.
- Unequal access to modern targeted therapies across countries
- Long delays between EMA approval and national reimbursement
- Fewer reimbursed treatment options in Central and Eastern Europe
- Regional disparities within countries (urban vs rural or administrative regions)
- Limited access to molecular and genetic testing (e.g., TP53, del17p)
- Variability in health technology assessment (HTA) processes
- Budget constraints limiting availability of high-cost therapies
- Inconsistent implementation of clinical guidelines
- Gaps in physician education on evolving CLL treatment standards
- Limited patient health literacy and understanding of disease/treatment
- Unequal availability of patient support services and advocacy resources
- Incomplete real-world data and outcome reporting across Europe
Let work together to address these issues. Join ECLLA!
ECLLA strengthens collaboration, advocacy and education at a continental level. It is essential to closing current care gaps and improving outcomes for all CLL patients, regardless of where they live.
#CLL #ECLLA #PatientAdvocacy